Daniel Marker, MD, PhD

Assistant Professor of Neuropathology, Assistant Director of the In-Situ Laboratory
Education & Training
BS, Biomolecular Science, Clarkson University, 2006
PhD, Neuroscience, University of Rochester, 2013
MD, University of Rochester, 2015
AP/CP Residency, UPMC, 2015-2019
Neuropathology Fellowship, UPMC, 2019-2021
Representative Publications

Marker DF, Pearce TM. Germ cell tumors of the central nervous system: A brief review and site-specific considerations. Semin Diagn Pathol. 2022 Jul 6:S0740-2570(22)00056-9. doi: 10.1053/j.semdp.2022.07.002. PMID: 35843756. 

Wu Z, Lopes Abath Neto O, Bale TA, Benhamida J, Mata D, Turakulov R, Abdullaev Z, Marker D, Ketchum C, Chung HJ, Giannini C, Quezado M, Pratt D, Aldape K. DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival. Acta Neuropathol. 2022 Jul;144(1):155-157. doi: 10.1007/s00401-022-02430-7. Epub 2022 May 14. PMID: 35567606. 

Marker DF, Agnihotri S, Amankulor N, Murdoch GH, Pearce TM. The dominant TP53 hotspot mutation in IDH -mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications. Neurooncol Adv. 2021 Dec 11;4(1):vdab182. doi: 10.1093/noajnl/vdab182. PMID: 35047821; PMCID: PMC8760900 

Marker DF, Pearce TM. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas. Acta Neuropathol Commun. 2020 Oct 20;8(1):169. doi: 10.1186/s40478-020-01044-y. PubMed PMID: 33081848; PubMed Central PMCID: PMC7574334.

Marker DF, Kofler JK, Mettenburg JA, Agha ME, Wiley CA. Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature. J Neuropathol Exp Neurol. 2020 Oct 1;79(10):1115-1121. doi: 10.1093/jnen/nlaa099. Review. PubMed PMID: 32954433; PubMed Central PMCID: PMC7559234.